

When we published Supplement 1 to issue 256/2006, we did not provide the conflict of interest information for the authors. They are as follows:

Möller HJ (2006) Editorial. Attention-deficit/hyperactivity disorder (ADHD) in adults. *Eur Arch Psychiatry Clin Neurosci* 256 (Suppl 1):I/2 [the original article can be found at <http://dx.doi.org/10.1007/s00406-006-1000-8>]:

Möller HJ. He reports conflict of interests. He has received research grants/support from, serves as a consultant or is on the advisory board for, or is a member of the speaker bureau for the following companies; Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Eisai, GlaxoSmithKline, Janssen Cilag, Lundbeck, Merck, Novartis, Organon, Pfizer, Sanofi Aventis, Sepracor, Servier, Wyeth

Rösler M, Retz W, Thome J, Schneider M, Stieglitz RD, Falkai P (2006). Psychopathological rating scales for the diagnostic use in adults with attention-deficit/hyperactivity disorder (ADHD). *Eur Arch Psychiatry Clin Neurosci* 256 (Suppl 1):I3–I11 [the original article can be found at <http://dx.doi.org/10.1007/s00406-006-1001-7>]:

Rösler M. He reports no conflict of interest. He is a member of the advisory boards of Medicie, Lilly Germany and UCB Europe. He is a member of the speaker bureau of Janssen-Cilag, Medicie and Lilly Germany. He has not received any financial compensation for this publication.

Retz W. He reports no conflict of interests. He is a member of the speaker bureau of Lilly Germany and Medice. He has not received financial support from Janssen-Cilag for this publication.

Thome J. He reports conflict of Interests having honoraria for lectures and scientific conferences.

Schneider M. He reports no conflict interests.

Stieglitz RD. He reports no conflict of interest.

Falkai P. He reports no conflict of interests. He is on the speaker bureau and/or consultant of Lilly, Janssen-Cilag, Pfizer, Lundbeck, Astra-Zeneca, and Bristol Myers Squibb.

Jacob C, Lesch KP (2006). The Wuerzburg Research Initiative on adult attention-deficit/hyperactivity disorder (WURIN-AADHD): multi layered evaluation of long-term course. *Eur Arch Psychiatry Clin Neurosci* 256 (Suppl 1):I12–I20 [the original article can be found at <http://dx.doi.org/10.1007/s00406-006-1002-6>]:

Jacob C. He has no conflicts of interest.

Lesch KO. He reports no conflict of interests.

Trott GE (2006). Attention-deficit/hyperactivity disorder (ADHD) in the course of life. *Eur Arch Psychiatry Clin Neurosci* 256 (Suppl 1):I21–I25 [the original article can be found at <http://dx.doi.org/10.1007/s00406-006-1003-5>]:

Trott GE. He reports no conflict of interest. He is a member of the speaker bureau of Eli Lilly, Janssen-Cilag, Novartis, Medice, Pfizer, Astra Zeneca. He negotiated the financial support for the print of the supplement with Janssen-Cilag.

---

Sobanski E (2006). Psychiatric comorbidity in adults with attention deficit/hyperactivity disorder (ADHD). *Eur Arch Psychiatry Clin Neurosci* 256 (Suppl 1):I26–I31 [the original article can be found at <http://dx.doi.org/10.1007/s00406-006-1004-4>]:

Sobanski E. She reports no conflict of interests.

Schneider M, Retz W, Coogan A, Thome J, Rösler M (2006). Anatomical and functional brain imaging in adult attention deficit hyperactivity disorder (ADHD)—a neurological view. *Eur Arch Psychiatry Clin Neurosci* 256 (Suppl 1):I32–I41 [the original article can be found at <http://dx.doi.org/10.1007/s00406-006-1005-3>]:

Coogan A. Reports no conflict of interest.

Rösler M. He reports no conflict of interest. He is a member of the advisory boards of Medicie, Lilly Germany and UCB Europe. He is a member of the speaker bureau of Janssen-Cilag, Medicie and Lilly Germany. He has not received any financial compensation for this publication.

Retz W. He reports no conflict of interests. He is a member of the speaker bureau of Lilly Germany and Medice. He has not received financial support with Janssen-Cilag for this publication.

Thome J. He reports Conflict of Interests having honoraria for lectures and scientific conferences.

Schneider M. He reports no conflict interests.

Philippsen A (2006). Differential diagnosis and comorbidity of attention deficit hyperactivity disorder (ADHD) and borderline personality disorder (BPD). *Eur Arch Psychiatry Clin Neurosci* 256 (Suppl 1):42–46 [the original article can be found at <http://dx.doi.org/10.1007/s00406-006-1006-2>]:

Philippsen A. She reports no conflict of interests.

Kordon A, Wahl KG, Wahl K (2006). A new understanding of attention-deficit disorder. Beyond the age at onset criterion of DSM-IV. *Eur Arch Psychiatry Clin Neurosci* 256 (Suppl 1):I47–I54 [the original article can be found at <http://dx.doi.org/10.1007/s00406-006-1007-1>]:

Kordon A. He reports being a member of the Janssen-Cialg, Lilly, Astra Zeneca, Lundbeck, Boehringer-Ingelheim, and Bristol Myers Squibb.

Wahl K. She reports no conflict of interests.

Kahl KG. He reports no conflict of interests.